Results 1 to 10 of about 158,262 (163)

Anticoagulation therapy after reperfusion treatment for acute ischemic stroke with non-valvular atrial fibrillation: a multicenter retrospective study [PDF]

Scientific Reports
To understand anticoagulation therapy in acute ischemic stroke (AIS) patients with non-valvular atrial fibrillation (NVAF) after receiving reperfusion treatments in the real world.
Fang Li, Jingjing Liu, Fan Zhang, Xiangbin Wu, Tingmin Dai, Jie Kuang, Zhijuan Cheng, Weiping Chen, Min Yin, Tinghao Guo, Guoyong Zeng, Jianglong Tu   +11 more
doaj   +2 more sources

Factors Affecting the Time in Therapeutic Range of Warfarin Anticoagulation Therapy in Patients with Atrial Fibrillation [PDF]

Clinical and Applied Thrombosis/Hemostasis
Objective To explore the factors affecting the Time in Therapeutic Range (TTR) of warfarin anticoagulation therapy and propose a novel TTR prediction model.
Xiao Luo MS, Qibao Zhou MS
doaj   +2 more sources

Electrochemical Monitoring in Anticoagulation Therapy [PDF]

Molecules
The process of blood coagulation, wherein circulating blood transforms into a clot in response to an internal or external injury, is a critical physiological mechanism.
Ashwin K. V. Mruthunjaya, Angel A. J. Torriero   +1 more
doaj   +2 more sources

Efficacy and safety of anticoagulation in atrial fibrillation patients with intracranial hemorrhage: A systematic review and meta-analysis

Frontiers in Pharmacology, 2023
Background: The benefits and risks of starting anticoagulation therapy, such as direct oral anticoagulations (DOACs) or warfarin, in atrial fibrillation (AF) patients with a history of intracranial hemorrhage (ICH) remain controversial.
Qiang Zhou, Xiang Liu, Xian Yang, Xiao-Hui Huang, Yan-Zi Wu, Ying-Ying Tao, Meng Wei   +6 more
doaj   +1 more source

Anticoagulation Before Hospitalization Is a Potential Protective Factor for COVID‐19: Insight From a French Multicenter Cohort Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Coronavirus disease 2019 (COVID‐19) is a respiratory disease associated with thrombotic outcomes with coagulation and endothelial disorders. Based on that, several anticoagulation guidelines have been proposed.
Richard Chocron, Vincent Galand, Joffrey Cellier, Nicolas Gendron, Thibaut Pommier, Olivier Bory, Lina Khider, Antonin Trimaille, Guillaume Goudot, Orianne Weizman, Jean Marc Alsac, Laura Geneste, Armand Schmeltz, Vassili Panagides, Aurélien Philippe, Wassima Marsou, Iannis Ben Abdallah, Antoine Deney, Salma El Batti, Sabir Attou, Philippe Juvin, Thomas Delmotte, Emmanuel Messas, Théo Pezel, Benjamin Planquette, Baptiste Duceau, Pascale Gaussem, Willy Sutter, Olivier Sanchez, Victor Waldman, Jean‐Luc Diehl, Tristan Mirault, Guillaume Bonnet, Ariel Cohen, David M. Smadja   +34 more
doaj   +1 more source

Clinical characteristics, management strategies and outcomes of patients with recurrent venous thromboembolism in the real world

Scientific Reports, 2022
There is a paucity of data on management strategies and clinical outcomes after recurrent venous thromboembolism (VTE). In a multicenter registry enrolling 3027 patients with acute symptomatic VTE, the current study population was divided into the ...
Yugo Yamashita, Takeshi Morimoto, Kazushige Kadota, Toru Takase, Seiichi Hiramori, Kitae Kim, Maki Oi, Masaharu Akao, Yohei Kobayashi, Mamoru Toyofuku, Moriaki Inoko, Tomohisa Tada, Po-Min Chen, Koichiro Murata, Yoshiaki Tsuyuki, Yuji Nishimoto, Jiro Sakamoto, Kiyonori Togi, Hiroshi Mabuchi, Kensuke Takabayashi, Takao Kato, Koh Ono, Takeshi Kimura   +22 more
doaj   +1 more source

Survival Benefit of Anticoagulation Therapy in End Stage Kidney Disease Patients with Atrial Fibrillation: A Single Center Retrospective Study

Medicina, 2021
Background and Objectives: Although the need for anticoagulation to prevent thromboembolism is increasing and non-vitamin K antagonist oral anticoagulants (NOACs) have been tried, there is still controversy about the efficacy of anticoagulation in ...
Mi-Ryung Kim, Deok-Gie Kim, Han-Wul Shin, Sung-Hwa Kim, Jae-Seok Kim, Jae-Won Yang, Byoung-Geun Han, Seong-Ok Choi, Jun Young Lee   +8 more
doaj   +1 more source

Association Between the Use of Pre- and Post-thrombolysis Anticoagulation With All-Cause Mortality and Major Bleeding in Patients With Pulmonary Embolism

Frontiers in Cardiovascular Medicine, 2022
ObjectiveTo explore the comparative clinical efficacy and safety outcomes of anticoagulation before (pre-) or following (post-) thrombolytic therapy in systemic thrombolytic therapy for pulmonary embolism (PE).MethodsPubMed, the Cochrane Library, EMBASE,
Jiang-Shan Tan, Ningning Liu, Ningning Liu, Song Hu, Yan Wu, Xin Gao, Ting-Ting Guo, Xin-Xin Yan, Fu-Hua Peng, Lu Hua   +9 more
doaj   +1 more source

Clinical prediction scores and early anticoagulation therapy for new-onset atrial fibrillation in critical illness: a post-hoc analysis

BMC Cardiovascular Disorders, 2021
Purpose This study sought to describe the epidemiology of anticoagulation therapy for critically ill patients with new-onset atrial fibrillation (NOAF) according to CHA2DS2-VASc and HAS-BLED scores and to assess the efficacy of early anticoagulation ...
Masaaki Sakuraya, Takuo Yoshida, Yusuke Sasabuchi, Shodai Yoshihiro, Shigehiko Uchino   +4 more
doaj   +1 more source

Time-trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF-STENT Registry. [PDF]

, 2020
BACKGROUND: The management of atrial fibrillation and flutter (AF) patients undergoing percutaneous coronary intervention (PCI) has undergone a rapid recent evolution. In 2016, the Canadian Cardiovascular Society (CCS) published expert recommendations to
Boivin-Proulx, L-A, Camm, JA, Deneault-Marchand, A, Fox, KAA, Gobeil, F, Mansour, S, Matteau, A, Potter, BJ   +7 more
core   +1 more source